Shares of Scienture Holdings, Inc. (NASDAQ: SCNX) are on a significant rise following the announcement of a key commercialization agreement. As of the latest premarket check, SCNX stock had surged 26.69%, reaching $2.80. The sharp increase reflects investor confidence in the company’s strategic initiative to enhance its commercial presence in the pharmaceutical sector.
Exclusive U.S. Rights for REZENOPY
Scienture Holdings announced that Summit Biosciences Inc., a division of Kindeva Drug Delivery L.P., and Scienture, LLC, a wholly owned subsidiary, have reached a final agreement. Through this collaboration, SCNX will have the only right to introduce and sell REZENOPY (naloxone HCl) Nasal Spray in the US.
The opioid antagonist was approved by the FDA on April 19, 2024, and is intended to successfully prevent opioid overdoses. The deal states that Scienture would maintain ownership of the new drug application (NDA), while Kindeva will be in charge of REZENOPY’s production and commercial supply.
In order to guarantee broad availability, SCNX will also oversee the product’s marketing, sales, and distribution throughout the United States by utilizing its infrastructure for commercial operations.
Increased Efficiency in Addressing the Opioid Epidemic
REZENOPY stands out as the strongest naloxone HCl formulation on the market right now. Its increased effectiveness against extremely strong opioids highlights how important it is to combating the current drug problem.
Scienture wants to work with advocacy groups, legislators, and medical experts to raise awareness, enhance education, and expedite distribution in light of the rising number of overdose-related deaths.
Market Prospects and Industry Influence
First responders and medical professionals rely heavily on the nasal administration of naloxone HCl because of its efficacy, accessibility, and ease of usage. The U.S. naloxone market produced $189 million in total yearly sales with a unit volume of 10 million, according to IQVIA statistics (MAT December 2024).
Scienture is well-positioned to play a significant part in increasing access to this necessary drug with the commercial launch of REZENOPY, reaffirming its leadership in tackling public health issues.